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Abstract
Background: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous
osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates
are anti-resorptive drugs which act mainly on osteoclasts.
Method: In this study, we have examined clinical and radiological outcomes of treatment with
aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four
European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from
GCTBs.
Results: Treatment protocols differed with several different aminobisphosphonates being employed, but
stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most
inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had
repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following
treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro.
Conclusion: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB
and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the
establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
Background
Giant cell tumour of bone (GCTB) accounts for around
5% of all primary bone tumours. GCTB is an expansile
osteolytic tumour which most often arises at the end of
a long bone in a skeletally mature patient [1,2]. Clini-
cally, most GCTB patients present with bone pain due
to enlargement of the tumour. GCTB is characterised by
t h ep r e s e n c eo fn u m e r o u sg i a nt cells that exhibit the
phenotypic features of mature osteoclasts [3]. The func-
tional definition of an osteoclast is that it is capable of
resorbing bone and, not surprisingly, GCTB is a tumour
that causes extensive osteolysis. GCTBs are actively
growing tumours which are often locally aggressive,
eroding the bone cortex and extending into surrounding
soft tissues [1,2]. Metastatic lesions, most commonly in
the lungs, can also develop in approximately 2% of
GCTB cases. The treatment of primary GCTBs is essen-
tially surgical and includes curettage (with or without
adjuvants such as phenol or liquid nitrogen) and exci-
sion of the affected area; however, surgical excision and
reconstruction is difficult as the tumour commonly
involves the epiphysis and the tumour arises in relatively
young patients, thus limiting surgical options. Reported
recurrence rates after curettage vary, depending upon
the thoroughness of curettage and the adjuvant treat-
ment employed, but are generally in the range of 25 to
50% [4-7].
Bisphosphonates are widely used to inhibit osteolysis
in conditions such as osteoporosis, Paget’sd i s e a s ea n d
metastatic cancer; these agents act by inhibiting
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[8-10]. Bisphosphonates have been used to treat osteoly-
tic benign tumour-like lesions such as fibrous dysplasia
and Langerhans cell histiocytosis that are not amenable
to surgery [11-14]. There are also a few reports of ami-
nobisphosphonate treatment of primary GCTBs which
have shown a variable but generally beneficial effect on
tumour size and recurrence rate [15,16]. There are no
reports, however, on the effect of bisphosphonate treat-
ment on recurrent or metastatic GCTBs.
Tumour osteolysis is mediated by osteoclasts [17,18],
and GCTB is a tumour that contains numerous osteo-
clasts. Bisphosphonates act primarily by inhibiting osteo-
clast-mediated resorption and it would seem logical that
GCTBs would benefit from bisphosphonate therapy. A
number of major European bone tumour centres have
tried using aminobisphosphonates to control disease
progression in problematic GCTB cases. Included
amongst these cases were persistently recurrent GCTBs
and large, pelvic or sacral GCTBs that were deemed
inoperable on account of difficulty in obtaining surgical
clearance, as well as a number of GCTB cases with evi-
dence of metastatic disease. The aim of this study is to
report the outcome of aminobisphosphonate treatment
of these GCTBs. We have also analysed the effect of
zoledronic acid (one of the most commonly employed
bisphosphonates) on lacunar resorption by osteoclasts
isolated directly from GCTBs in order to provide in
v i t r oe v i d e n c ef o rt h ei n h i b i t o r ye f f e c to fa m i n o b i s p h o -
sphonates on GCTB osteolysis.
Methods
Clinical studies: Aminobisphosphonate-treatment of GCTB
cases
25 GCTB cases which had received aminobisphospho-
nate treatment were recruited from partners in the
EuroBoNet consortium. The bisphosphonate treatment
protocol was approved by the ethics review board of
each participating institution. The study was carried out
in accordance with the ethical principles of the Declara-
tion of Helsinki and good clinical practice. All patients
provided written informed consent before treatment. 11
cases were obtained from the Istituti Ortopedici Rizzoli,
Bologna, 4 from The Nuffield Orthopaedic Centre,
Oxford, 7 from Westfalische Wilhmsuniversitai, Mun-
ster, and 4 from Leiden University Medical Centre, Lei-
den. Clinical details of these bisphosphonate-treated
cases, including sex, age, site of tumour, episodes of
tumour recurrence following surgery and evidence of
metastasis, are shown in Table 1. All cases included in
this study were Enneking Stage 1B or 3B.
Indications for patient referral for bisphosphonate
treatment differed between the various centres. Most
centres used bisphosphonates for the treatment of
recurrent or metastatic disease or for primary inoperable
pelvic/sacral tumours. In some cases, additional adjuvant
therapy, such as embolisation, radiation therapy or other
drugs (eg interferon alpha) were also used to control
progressive disease. Zoledronic acid was the most com-
monly employed bisphosphonate; other bisphosphonates
employed included alendronate, clodronate, pamidro-
nate. The doses of these drugs and the methods of
administration differed between the various centres.
Oral alendronate was given continuously at a dose of 70
mg/week, to patients 1 and 7 for 24 months and 32
months respectively; oral clodronate was given 2 × 800
mg/day for 36, 12, 60 and 50 months to patients 2, 3, 4
and 6. Pamidronate, 90 mg/month was given intrave-
nously to case 5. Zoledronic acid (4 mg) was given
intravenously as a single infusion in cases 10, 20, 21;
two infusions were given to cases 19, 22, 24; other cases
received up to 6 intravenous infusions of zoledronic
acid over a variable period of time. Protocols of drug
administration varied between the centres but were gen-
erally correlated with tumours i z ea n dt h er e s p o n s et o
treatment. The period of follow-up following treatment
ranged from 36 to 64 months.
Primary, recurrent or metastatic GCTBs were regu-
larly evaluated for disease progression. The effect of
bisphosphonate treatment on tumour size was assessed
radiologically by a variety of techniques including X-ray,
MRI and CT. Clinical outcome was not assessed for-
mally but when patients volunteered that their pain had
decreased following treatment, this was noted. In
patients with recurrent GCTBs in bone or soft tissue, it
was also noted whether further recurrences occurred
following therapy.
Cell culture studies: Analysis of the effect of zolendronate
on osteoclasts obtained from GCTB
Alpha minimum essential medium (aMEM) and fetal
bovine serum (FBS) were purchased from Gibco Labora-
tories (Paisley, Scotland); aMEM containing 10% FBS,
100 U/ml penicillin, and 100 μg/ml streptomycin
(MEM/FBS) was used for cell culture experiments. Zole-
dronic acid was obtained from Novartis (Basel,
Switzerland).
Isolation of osteoclastic giant cells from GCTB cases
was carried out as previously described [3]. Fresh tissue
from four cases of GCTB, two (cases 11 and 12) of
which were included among the clinical cases studied,
was obtained at the time of surgery at the Nuffield
Orthopaedic Centre, Oxford. GCTB tumour tissue was
washed in sterile phosphate buffered saline (PBS). Frag-
ments of tumour were curetted in aMEM/FBS and the
cell suspension was added to dentine slices and glass
coverslips in a 96-well plate (approximately 30 giant
cells per well). After 2 hours incubation at 37°C in a
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Sex/Age Tumour Site Pre treatment
Recurrence/
Metastasis
Post treatment
Follow-up
(months)
Type of bisphosphonate (and
other) treatment employed
Post treatment
Radiological/Clinical
Outcome
1. M 39 Distal femur RRR/- 24 Alendronate Pain decrease No further
recurrence
2. F 28 Sacrum */- 36 Clodronate (Interferon a,
Radiation)
Pain decrease Stable size
3. M 63 Distal femur R/M 12 Clodronate (Interferon a) No further recurrence Lung
mets stable
4. M 16 Distal Femur, Proximal
Femur, Proximal Tibia
(Multifocal)
R/M 60 Clodronate (Interferon a, Cis-
platin, Adriamycin)
Stable size Lung mets
stable
5. M 20 Proximal Femur RR/M 64 Pamidronate (Interferon a) No further recurrence Lung
mets stable
6. M 47 Pelvis R/- 50 Clodronate (Radiation) Stable size
7. F 56 Sacrum R/- 32 Alendronate (Radiation,
Embolisation)
Pain decrease Stable size
8. F 75 Sacrum */- 24 Zoledronic acid Stable size
9. F 42 Proximal Femur RRRRR/- 24 Zoledronic acid No further recurrence Pain
decrease
10. M 34 Vertebra RR/- 12 Zoledronic acid (Radiotherapy,
Embolisation)
Stable size Recurrence
11. M 32 Fibula RR(ST)/M 62 Zoledronic acid Pain decrease No further
recurrence Lung mets
stable
12. F 21 Sacrum RR/- 60 Zoledronic acid (Embolisation) Disease progression
13. F 45 Sacrum M 12 Zoledronic acid (Embolisation) Decrease in size Pain
decrease
14. M 74 Pelvis */- 26 Zoledronic acid (Embolisation) Pain decrease Stable size
Paget’s
15. F 19 Sacrum R/- 15 Zoledronic acid (Embolisation) Stable size No further
recurrence
16. F 48 Sacrum R/- 24 Zoledronic acid
a (Embolisation) Stable size No further
recurrence
17. M 15 Sacrum R/- 12 Zoledronic acid
a (Embolisation) Stable size No further
recurrence
18. F 22 Distal Femur (multifocal) RR/M 12 Zoledronic acid Disease progression
19. F 17 Proximal tibia R/M 24 Zoledronic acid (Interferon a,
Cyclophosphamide, Ifosfamide)
Lung mets stable No further
recurrence
20. F 32 Pelvis R/M 24 Zoledronic acid (Radiation,
Embolisation)
Stable size Lung mets
stable
21. F 64 Proximal tibia R/M Zoledronic acid (Embolisation) No further recurrence Lung
mets stable
22. F 30 Proximal humerus -/- 24 Zoledronic acid Pain decrease No further
recurrence
23. F 49 Sacrum R/M 3 Zoledronic acid (Embolisation) Disease progression
24. F 31 Fibula (ST)RR/M 30 Zoledronic acid
a Lung mets stable No further
recurrence
25. F 51 Distal radius RR/M 8 Zoledronic acid Lung mets stable
* No surgical treatment
a - intra-op zoledronic acid for treatment of recurrent tumour
ST - soft tissue recurrence
R - episode of recurrence
M - lung metastasis
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tine slices and glass coverslips were washed in MEM/
FBS to remove any non-adherent cells. Fresh MEM/FBS
was then added and the cells were incubated in the pre-
sence and absence of zoledronic acid (4 × 10
-5 M). Cul-
tures on dentine slices were maintained for up to 48
hours and including 24 hours at 37°C, then treated with
1 M ammonium hydroxide, washed in distilled water
and ultrasonicated to remove adherent cells; these slices
were then stained with 0.5% (W/v) toluidine blue to
reveal areas of lacunar resorption and examined by light
microscopy. The percentage surface area of lacunar
resorption on each dentine slice was measured using
image analysis software (Adobe Photoshop CS2, USA)
as previously described [3].
Results
Effect of bisphosphonate treatment on primary, recurrent
and metastatic GCTBs
Details of treatment, period of follow-up following ther-
apy and radiological/clinical outcome are shown in
Table 1. None of the patients reported complications
related to bisphosphonate treatment.
The majority of large primary sacral/pelvic GCTBs,
three of which were deemed inoperable, did not increase
in size following treatment. Tumours did not disappear
or regress but remained stable in size. In two cases,
increased calcification developed around and within the
lesion (Figure 1). With the exception of one spinal and
one sacral GCTB, both of which recurred following sur-
gery, the other spinal and pelvic GCTB cases did not
exhibit disease progression. Of the cases that recurred,
one was a spinal GCTB which developed recurrence after
incomplete excision 24 months after Zoledronic acid
treatment (case 12); the other case was on Zoledronic
acid treatment for only three months and died intra-
operatively with extensive pelvic disease (case 23).
Almost all sacral and pelvic tumours were also treated by
embolisation and four cases received radiation therapy.
Seven patients received pre-operative or intra-opera-
tive Zoledronic acid for treatment of repeated recur-
rence of large GCTBs arising in the skeleton. Although
several different types of bisphosphonate were employed
(using different dosage and methods of administration),
stabilisation of tumour size and some pain relief was
noted. This beneficial effect was not restricted to the
use of one type of aminobisphosphonate or method of
administration, cases 1-7 receiving alendronate or clo-
dronate orally, case 5 receiving Pamidronate and cases
8-25 receiving Zoledronic acid parenterally. Further
recurrences did not occur after treatment in most cases
and in two cases (cases 11 and 24), where two episodes
of soft tissue recurrence had previously occurred, no
further soft tissue recurrence developed.
Twelve of the cases developed lung metastases of GCTB.
One of these cases had a multifocal GCTB with lung
metastases. Two of the cases had metastases at the time of
initial diagnosis (cases 11 and 13). In the other cases,
metastases appeared following development of recurrent
GCTBs. Metastases did not increase in size or number fol-
lowing bisphosphonate treatment as assessed by lung CT
and chest X-ray. In one case (case 3) the CT findings were
reported as showing a slight decrease in the size of lung
metastases. No patient with metastatic disease developed
further lung nodules whilst under treatment.
Effect of Zoledronic acid on lacunar resorption by GCTB-
derived osteoclasts
Multinucleated cells isolated from GCTB expressed the
antigenic phenotype of osteoclasts, being TRAP and
CD51 positive and CD14 negative [3,19]. The multinu-
cleated giant cells were large and had abundant cyto-
plasm with broad pseudopodia. Lacunar bone resorption
is the definitive functional criterion of an osteoclast and
the GCTB-derived multinucleated cells were capable of
carrying out lacunar resorption in short term culture.
The addition of zoledronic acid (4 × 10
-5 M) to 24 hour
cultures of GCTB-derived osteoclasts resulted in inhibi-
tion of lacunar resorption (Figure 2). The lacunar
resorption in zoledronic acid-treated osteoclast cultures
derived from two GCTB cases was 16% and 25% of that
seen in untreated GCTB control osteoclast cultures and,
i no n ec a s e ,aG C T Bi nw h i c ht h e r ew a se x t e n s i v e
aneurysmal bone cyst change, resorption activity was
entirely abolished by zoledronic acid. Inhibition of
resorption activity was not uniformly profound as one
case showed only a 21% reduction in lacunar resorption
relative to control osteoclast cultures.
Discussion and Conclusions
GCTB commonly recurs after curettage and complete
excision is often not possible due to the size and loca-
tion of the tumour. This study reports the experience of
four European centres which have employed aminobi-
sphosphonates as a component of adjuvant treatment
for problematic primary (inoperable), recurrent and
metastatic GCTBs. Although results are difficult to
assess as the problematic nature of the cases studied
meant that results could not be compared with a single
control group, and aminobisphosphonates were adminis-
tered on an individual ad hoc basis, often in combina-
tion with other adjuvant therapies, they are of interest
as they show that most tumours did not increase in size
after bisphosphonate treatment and that control of
tumour recurrence and pain was achieved in some cases.
Actively growing GCTBs are associated with extensive
bone resorption. Bisphosphonate treatment is well-
established in controlling osteolysis associated with
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ple myeloma [8,9], and bisphosphonates have also been
used to control osteolysis occurring as a result of fibrous
dysplasia and Langherans cell histiocytosis [12-14]. Two
recent studies have reported the use of bisphosphonates
in GCTB. Tse et al [16] studied 24 patients treated with
either pamidronate or zoledronic acid given preopera-
tively and found that only one of 24 patients (4.2%)
developed local recurrence following this treatment; this
contrasted to the control group who had a recurrence
rate of 30%. There is also a report on the use of intrave-
nous bisphosphonate to control the growth of a giant
cell tumour of the sacrum [15]. As in our series of
cases, the patients receiving aminobisphosphonates for
GCTB in these two reports, did not complain of signifi-
cant treatment side effects.
Figure 1 MRI of GCT pre and post zoledronic acid treatment. Axial T2- weighted (fat-suppressed) MRI of (a) pre and (b) 5 year post-
zoledronic acid treatment of Case 12, an enlarging sacral/pelvic GCTB which shows stabilisation of tumour size. Following treatment there is
some evidence of infilling of the lytic tumour (arrowed) following zoledronic acid treatment.
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Page 5 of 8Figure 2 GCT osteoclast resorption. (a) control and (b) zoledronic acid-treated cultures of GCTB-derived osteoclasts on dentine slices, showing
marked inhibition of lacunar resorption pit formation in zoledronic acid-treated cultures.
Balke et al. BMC Cancer 2010, 10:462
http://www.biomedcentral.com/1471-2407/10/462
Page 6 of 8Our results show that most inoperable primary sacral
and pelvic GCTBs did not continue to increase in size
after commencing oral or intravenous aminobispho-
sphonate treatment with some cases showing radiologi-
c a le v i d e n c eo fb o n ef o r m a t i on and infilling of lytic
lesions. Treatment also resulted in control of cases of
persistently recurrent GCTB. Bisphosphonates are
recognised to have an analgesic effect on bone tumours
[20], and a decrease in pain was noted in some of the
treated cases. This was most notable in case 13 where
significant pain relief was achieved following zoledronic
acid treatment of a large sacral tumour compressing the
sciatic nerve; this tumour stabilized in size, developed a
sclerotic border and showed infilling with bone; this
patient is currently pain-free. The effect of bisphospho-
nates on metastatic lung lesions of GCTB was more dif-
ficult to evaluate as it is known that these lesions can
remain stable in size for many years or even regress.
However, it was noted that lung nodules of GCTB did
not increase in size and no further nodules developed in
the course of bisphosphonate treatment.
The tissue specific targeting of bisphosphonates to the
mineral component in bone is extremely useful in con-
trolling the growth of bone lesions. Bisphosphonates are
non-toxic analogues of pyrophosphate which are known
to inhibit osteoclast-mediated bone resorption. Binding
of bisphosphonates to hydroxyapatite results in changes
in the physico-chemical structure of the hydroxyapatite
crystal [8-10]. Aminobisphosphonates act by inhibiting
farnesyl diphosphate synthase, an enzyme in the mevalo-
nate pathway. This results in inhibition of osteoclast for-
mation from mononuclear phagocyte precursors,
decreased osteoclast resorption due to effects on the
cytoskeleton, vesicular trafficking and membrane ruf-
fling, and increased osteoclast apoptosis [21-23]. It has
been shown that bisphosphonate treatment induces
apoptosis of GCTB stromal cells and osteoclasts [24-26].
An inhibitory effect of zoledronic acid on GCTB-derived
osteoclast resorption in vitro was noted in this study; in
three of the four cases osteoclast resorption was abol-
ished or profoundly inhibited whereas in one case the
decrease in resorption (21%) was more modest. This is
in keeping with the findings of Lau et al [3], who also
noted a pronounced but variable inhibitory response to
zoledronic acid by GCTB-derived osteoclasts. This varia-
tion in the inhibitory effect of zoledronic acid on osteo-
clasts derived from different GCTBs may reflect
differences in the therapeutic effect of bisphosphonates
in our study.
GCTB contains numerous mature, functional osteo-
clasts. The rationale for using bisphosphonates to con-
trol the osteolysis associated with the growth of GCTBs
is that these compounds reduce osteoclast numbers in
bone and inhibit osteoclastic resorption. A similar
rationale underlies treatment of GCTB with denosumab,
an anti-RANKL antibody; this has been reported to
result in clinical and radiological improvement in some
cases [27]. Aminobisphosphonates have an established
role in the treatment of tumour osteolysis associated
with metastatic cancer and our results show that these
drugs can achieve stabilisation of disease in problematic
GCTB cases. The use of different bisphosphonates and
protocols of treatment, as well as the effect of other
adjuvant therapies, needs to be taken into consideration
when evaluating the results of this study. None of the
patients in our study reported significant side effects fol-
lowing bisphosphonate treatment but it should be borne
in mind that long-term therapy with bisphosphonates
can be associated with significant complications, notably
osteonecrosis of the jaw [28].
Further studies to analyse the effect of aminobispho-
sphonates on GCTB would seem appropriate, particularly
in the context of controlling the progressive bone destruc-
tion and enlargement of inoperable large primary GCTBs
and problematic bone and soft tissue GCTB recurrences.
It may be worthwhile examining whether combined deno-
sumab and bisphosphonate treatment is more effective in
controlling osteolysis or in alleviating bone pain; the latter
can be assessed using standardised scores eg functional
assessment of cancer therapy-bone pain [29]. Our study
highlights the fact that there is no recognised protocol for
aminobisphosphonate treatment of GCTB tumours in
Europe (or elsewhere in the world to our knowledge), and
that there is a need to establish standardised protocols not
only for the administration of these drugs but also for defi-
nition of outcome measures that will permit a reliable
assessment of treatment efficacy.
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